A bispecific anti-fluorescein x anti-CD3 T-cell engager in combination with fluoresceinated adaptors enables lysis of AML cells - PubMed
5 hours ago
- #immunotherapy
- #AML
- #T-cell engager
- A bispecific anti-fluorescein x anti-CD3 T-cell engager (AdFITC-TCE) combined with fluoresceinated adaptors enables lysis of AML cells.
- AdFITC-TCE activates T-cells against acute myeloid leukemia (AML) by recognizing CD3ε on T-cells and fluorescein on tumor-bound adaptors.
- The approach allows for multi-plexing by targeting multiple antigens through fluoresceinated antibody constructs against CD33 and CD117.
- AdFITC-TCE plus fluoresceinated adaptors and T-cells inhibits AML cell growth in NSG mice in vivo, with efficacy similar to AdFITC-CAR T-cells.
- AdFITC-TCE is a versatile tool that can activate T-cells for target cell lysis when combined with any fluoresceinated binder.